Entero Therapeutics (NASDAQ:GRDX) Issues Quarterly Earnings Results

Entero Therapeutics (NASDAQ:GRDX) posted its quarterly earnings results on Friday. The company reported ($1.88) EPS for the quarter, FiscalAI reports.

Entero Therapeutics Stock Up 0.4%

Shares of Entero Therapeutics stock traded up $0.01 during trading hours on Friday, reaching $2.52. The stock had a trading volume of 44,014 shares, compared to its average volume of 122,654. The company’s 50 day simple moving average is $2.28. The stock has a market cap of $8.47 million, a price-to-earnings ratio of -1.49 and a beta of 1.10. Entero Therapeutics has a twelve month low of $1.01 and a twelve month high of $5.84.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC purchased a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned about 1.45% of Entero Therapeutics as of its most recent SEC filing. 12.30% of the stock is currently owned by hedge funds and other institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.